Drug-drug interactions between vitamin K antagonists and statins: a systematic review

Anna E. Engell; Andreas L.O. Svendsen; Bent S. Lind; Tore Bjerregaard Stage; Maja Hellfritzsch; Anton Pottegård

doi:10.1007/s00228-020-03074-w

Drug-drug interactions between vitamin K antagonists and statins: a systematic review

Anna E. Engell^*
, Andreas L.O. Svendsen
, Bent S. Lind
, Tore Bjerregaard Stage
, Maja Hellfritzsch
, Anton Pottegård

^*Corresponding author for this work

Clinical Pharmacology, Pharmacy and Environmental Medicine

Hvidovre Hospital
University of Copenhagen
Aarhus University Hospital

Research output: Contribution to journal › Journal article › Research › peer-review

94 Downloads (Pure)

Abstract

Purpose: Concomitant use of vitamin K antagonists (VKA) and statins is frequent in cardiovascular patients. However, clinical guidelines on this drug combination are divergent. Therefore, we performed a systematic review to evaluate the effect of statin initiation on coagulation among VKA users. Methods: Following the PRISMA guidelines, we applied two broad search strategies for the drug interaction between VKA and statins in both Embase and Pubmed; 8623 unique hits were obtained. In the final sample, eight studies were included. Results: The most frequently used VKA in the studies was warfarin, while simvastatin was the most commonly initiated statin. All included studies showed a minor increase in the anticoagulant effect of VKA following statin initiation during VKA treatment. The reported increases in mean international normalized ratio (INR) ranged from 0.15–0.65. Conclusion: The anticoagulant effect of statin initiation in patients treated with VKA is likely to be of limited clinical relevance but should be evaluated individually.

Original language	English
Journal	European Journal of Clinical Pharmacology
Volume	77
Issue number	10
Pages (from-to)	1435-1441
ISSN	0031-6970
DOIs	https://doi.org/10.1007/s00228-020-03074-w
Publication status	Published - Oct 2021

Funding

TBS reports personal fees from Pfizer, Eisai, and Astellas Pharma, outside the submitted work. TBS has done consulting and paid lectures for Pfizer and paid lectures for Eisai and Astellas Pharma with no relation to the submitted work. AP reports participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Novo Nordisk, Servier, and LEO Pharma, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work.

Keywords

Anticoagulants
Drug interactions
Statins
Vitamin K antagonists
Warfarin

Documents & Links

10.1007/s00228-020-03074-w

Open Access VersionAccepted manuscript, 288 KB

SDU Link

Check access to the material in SDU Library's search engine

Cite this

@article{16614ed5f7cb4308aa77dad8315637f2,

title = "Drug-drug interactions between vitamin K antagonists and statins: a systematic review",

abstract = "Purpose: Concomitant use of vitamin K antagonists (VKA) and statins is frequent in cardiovascular patients. However, clinical guidelines on this drug combination are divergent. Therefore, we performed a systematic review to evaluate the effect of statin initiation on coagulation among VKA users. Methods: Following the PRISMA guidelines, we applied two broad search strategies for the drug interaction between VKA and statins in both Embase and Pubmed; 8623 unique hits were obtained. In the final sample, eight studies were included. Results: The most frequently used VKA in the studies was warfarin, while simvastatin was the most commonly initiated statin. All included studies showed a minor increase in the anticoagulant effect of VKA following statin initiation during VKA treatment. The reported increases in mean international normalized ratio (INR) ranged from 0.15–0.65. Conclusion: The anticoagulant effect of statin initiation in patients treated with VKA is likely to be of limited clinical relevance but should be evaluated individually.",

keywords = "Anticoagulants, Drug interactions, Statins, Vitamin K antagonists, Warfarin",

author = "Engell, \{Anna E.\} and Svendsen, \{Andreas L.O.\} and Lind, \{Bent S.\} and Stage, \{Tore Bjerregaard\} and Maja Hellfritzsch and Anton Potteg{\aa}rd",

note = "Funding Information: TBS reports personal fees from Pfizer, Eisai, and Astellas Pharma, outside the submitted work. TBS has done consulting and paid lectures for Pfizer and paid lectures for Eisai and Astellas Pharma with no relation to the submitted work. AP reports participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Novo Nordisk, Servier, and LEO Pharma, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work. ",

year = "2021",

month = oct,

doi = "10.1007/s00228-020-03074-w",

language = "English",

volume = "77",

pages = "1435--1441",

journal = "European Journal of Clinical Pharmacology",

issn = "0031-6970",

publisher = "Springer Science+Business Media",

number = "10",

}

TY - JOUR

T1 - Drug-drug interactions between vitamin K antagonists and statins

T2 - a systematic review

AU - Engell, Anna E.

AU - Svendsen, Andreas L.O.

AU - Lind, Bent S.

AU - Stage, Tore Bjerregaard

AU - Hellfritzsch, Maja

AU - Pottegård, Anton

N1 - Funding Information: TBS reports personal fees from Pfizer, Eisai, and Astellas Pharma, outside the submitted work. TBS has done consulting and paid lectures for Pfizer and paid lectures for Eisai and Astellas Pharma with no relation to the submitted work. AP reports participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Novo Nordisk, Servier, and LEO Pharma, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work.

PY - 2021/10

Y1 - 2021/10

N2 - Purpose: Concomitant use of vitamin K antagonists (VKA) and statins is frequent in cardiovascular patients. However, clinical guidelines on this drug combination are divergent. Therefore, we performed a systematic review to evaluate the effect of statin initiation on coagulation among VKA users. Methods: Following the PRISMA guidelines, we applied two broad search strategies for the drug interaction between VKA and statins in both Embase and Pubmed; 8623 unique hits were obtained. In the final sample, eight studies were included. Results: The most frequently used VKA in the studies was warfarin, while simvastatin was the most commonly initiated statin. All included studies showed a minor increase in the anticoagulant effect of VKA following statin initiation during VKA treatment. The reported increases in mean international normalized ratio (INR) ranged from 0.15–0.65. Conclusion: The anticoagulant effect of statin initiation in patients treated with VKA is likely to be of limited clinical relevance but should be evaluated individually.

AB - Purpose: Concomitant use of vitamin K antagonists (VKA) and statins is frequent in cardiovascular patients. However, clinical guidelines on this drug combination are divergent. Therefore, we performed a systematic review to evaluate the effect of statin initiation on coagulation among VKA users. Methods: Following the PRISMA guidelines, we applied two broad search strategies for the drug interaction between VKA and statins in both Embase and Pubmed; 8623 unique hits were obtained. In the final sample, eight studies were included. Results: The most frequently used VKA in the studies was warfarin, while simvastatin was the most commonly initiated statin. All included studies showed a minor increase in the anticoagulant effect of VKA following statin initiation during VKA treatment. The reported increases in mean international normalized ratio (INR) ranged from 0.15–0.65. Conclusion: The anticoagulant effect of statin initiation in patients treated with VKA is likely to be of limited clinical relevance but should be evaluated individually.

KW - Anticoagulants

KW - Drug interactions

KW - Statins

KW - Vitamin K antagonists

KW - Warfarin

U2 - 10.1007/s00228-020-03074-w

DO - 10.1007/s00228-020-03074-w

M3 - Journal article

C2 - 33895864

AN - SCOPUS:85105358360

SN - 0031-6970

VL - 77

SP - 1435

EP - 1441

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

IS - 10

ER -

Drug-drug interactions between vitamin K antagonists and statins: a systematic review

Abstract

Funding

Keywords

Documents & Links

SDU Link

Fingerprint

Cite this